Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Change in Accured Expenses (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Change in Accured Expenses readings, the most recent being -$1.4 million for Q1 2026.

  • Quarterly Change in Accured Expenses fell 140100.0% to -$1.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.5 million through Mar 2026, down 226.75% year-over-year, with the annual reading at -$1.1 million for FY2025, 98.88% down from the prior year.
  • Change in Accured Expenses hit -$1.4 million in Q1 2026 for Ovid Therapeutics, down from $2.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.1 million in Q2 2024 and bottomed at -$3.4 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is -$244270.9, with a median of -$1000.0 recorded in 2025.
  • The largest annual shift saw Change in Accured Expenses surged 229.55% in 2025 before it tumbled 140100.0% in 2026.
  • Ovid Therapeutics' Change in Accured Expenses stood at -$1.2 million in 2022, then surged by 125.36% to $303000.0 in 2023, then crashed by 622.77% to -$1.6 million in 2024, then surged by 229.55% to $2.1 million in 2025, then crashed by 168.32% to -$1.4 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Change in Accured Expenses are -$1.4 million (Q1 2026), $2.1 million (Q4 2025), and $27000.0 (Q3 2025).